Secretin and Autism Ranking: Mildly Hazardous Very strong negative evidence

Syringe Secretin is a gastrointestinal hormone that helps to promote digestion of food.

It stimulates the stomach to produce the enzyme pepsin, the liver to produce bile, and the pancreas to produce digestive juices that help neutralize acidity in the intestines.

The main medical use of secretin is as a diagnostic tool in various disorders of the pancreas (such as gastrinoma). 

Some people believe that secretin can be used to treat gastrointestinal problems (such as constipation and diarrhoea) in autistic people. They also believe that treating those gastrointestinal problems will lead to improvements in other areas (such as sociability, speech, and sleep).

Please Note

The National Institute of Health and Clinical Excellence (NICE) made the following recommendation.

'Do not use secretin for the management of core symptoms of autism in adults.' (NICE, 2012)

Our Opinion

There is a reasonable amount of research evidence (17 group studies and four single-case design studies) into the use of secretin for autistic individuals.

The vast majority of those studies reported no benefits of any kind and some reported adverse effects (such as an increase in challenging behaviours). 

A minority of lower quality studies reported a range of benefits (such as improved gastrointestinal symptoms, alongside improved eye contact and alertness) in a sub-group of participants. However those benefits failed to reach statistical significance, meaning that they could have happened as the result of chance.  

There is evidence from a range of sources to suggest that secretin may sometimes cause potentially harmful effects.

We believe that the theory behind the use of secretin as a treatment for autistic people is weak and unproven. We also believe that the research evidence suggests that secretin provides no real benefits for autistic people.

Because of this we cannot recommend the use of secretin for autistic people. 


Please read our Disclaimer on Autism Interventions

16 Jun 2022
Last Review
01 Dec 2018
Next Review
01 Aug 2024